Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer (Industry)

Overall Status

Completed

CT.gov ID

NCT00247429

Collaborator

(none)

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.

Condition or Disease	Intervention/Treatment	Phase
Depressive Syndrome Anxiety

Study Design

Study Type:

Observational

Actual Enrollment :

59 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Vandral Retard (Venlafaxine Extended Release) in Depressive Syndrome With Anxiety and Painful Symptoms in Elderly Patients. Observational Study in Primary Care

Study Start Date :

Jul 1, 2004

Actual Primary Completion Date :

Oct 1, 2005

Actual Study Completion Date :

Oct 1, 2005

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients older than 60 years
Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14

Exclusion Criteria:

Participation in other studies in the last 3 months before the start of the study
Known hypersensibility to venlafaxine
Clinically significant abnormalities according to the venlafaxine labeling